Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Established in 1950, Taro Pharmaceutical Industries Ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. Taro’s research programs and niche strategy have enabled the Company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO) and certain of its officers.

TARO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

MILWAUKEE , Sept. 10, 2024 /PRNewswire/ -- Ademi LLP announces that a class action lawsuit has been filed on September 9, 2024 in the United States District Court for the Southern District of New York, captioned Mitchell v.

Ademi LLP announces the filing of Class Action Lawsuit against Taro Pharmaceutical Industries Ltd. and other Defendants

Combined entity is better positioned to compete in increasingly competitive generics industry MUMBAI, India and PRINCETON, N.J. , June 24, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd.

Sun Pharma Completes Taro Merger

MUMBAI, India and NEW YORK , May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro shareholders unaffiliated with Sun Pharma) at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024.

Taro Shareholders Approve Merger with Sun Pharma

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR YEAR ENDED MARCH 31, 2024.

Taro Provides Results for Year Ended March 31, 2024

MILWAUKEE , May 20, 2024 /PRNewswire/ -- Ademi LLP is investigating Taro (NYSE: TARO) for possible breaches of fiduciary duty and other violations of law in its transaction with its majority shareholder Sun. Click here to learn how to join the https://www.ademilaw.com/case/taro-pharmaceutical-industries-limited or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Taro Pharmaceutical Industries Limited has obtained a Fair Price for its Public Shareholders in its transaction with its majority shareholder, Sun Pharmaceutical Industries Limited.

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO RELEASE FULL YEAR RESULTS ON MAY 20, 2024.

Taro to Release Full Year Results on May 20, 2024

NEW YORK--(BUSINESS WIRE)--Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Taro will receive $43.00 in cash for each share of Taro that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.

TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO

NEW YORK--(BUSINESS WIRE)--Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.

Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.

NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical Industries Ltd.

Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Release Third Quarter Results on January 25, 2024.

Taro to Release Third Quarter Results on January 25, 2024

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) to Sun Pharmaceutical Industries Limited for $43.00 per share in cash is fair to Taro shareholders. Halper Sadeh encourages Taro shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation c.

TARO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Taro Pharmaceutical Industries Ltd. Is Fair to Shareholders

Agreed Price of US$43.00 per Share to Deliver 48% Premium to Unaffected Price on May 25, 2023 MUMBAI, India and NEW YORK , Jan. 17, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro's controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for US$43.00 per share in cash without interest.

Taro Announces Merger Agreement with Sun Pharma

Taro (TARO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Taro (TARO) is on the Move, Here's Why the Trend Could be Sustainable

Taro Pharmaceutical Industries is a hidden treasure in the pharmaceutical industry, with a Strong Buy Quant Rating and positive financials. The company has been overshadowed by Teva Pharmaceutical Industries but has potential for growth in its niche. Taro's recent earnings report showed increased sales and profitability, making it an attractive investment opportunity.

Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity

Taro (TARO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Taro (TARO) Rating Upgrade to Strong Buy

Taro Pharmaceutical (TARO) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago.

Taro Pharmaceutical (TARO) Tops Q2 Earnings Estimates

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Release Second Quarter Results on October 26, 2023.

Taro to Release Second Quarter Results on October 26, 2023

Compugen

Gamida Cell Ltd

Kamada

Protalix Biotherapeutics

Teva Pharmaceutical

Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR THE QUARTER ENDED JUNE 30, 2023.

Taro Provides Results for the Quarter Ended June 30, 2023

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO RELEASE FIRST QUARTER RESULTS ON JULY 26, 2023.

Taro to Release First Quarter Results on July 26, 2023

NEW YORK , July 19, 2023 /PRNewswire/ -- As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Krensavage Asset Management LLC opposes Sun Pharmaceutical Industries Ltd.

Krensavage Asset Management Opposes Sun's Lowball Bid for Taro

Taro received a $38/share offer from Sun Pharma last month. The deal represents a decent premium to the firm's market value at the time and a 12% premium to my estimate of fair value. Further insights reveal the deal could be valuable to Taro shareholders given all the contributing factors.

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

Taro saw rising revenue in the fourth quarter but falling net income. Sun Pharmaceutical already owns 78.5% of Taro's shares.

News for Taro Pharmaceutical Industries Stock (TARO)